Cargando…
Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study
BACKGROUND: Inflammation is considered one of the major causes of protein-energy wasting in maintenance hemodialysis (MHD) patients. It is unclear whether dietary interventions can impact nutritional status and quality of life in MHD patients with elevated C-reactive protein (CRP) levels. Therefore,...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477490/ https://www.ncbi.nlm.nih.gov/pubmed/26099512 http://dx.doi.org/10.1186/s12882-015-0070-0 |
_version_ | 1782377771823005696 |
---|---|
author | Beddhu, Srinivasan Filipowicz, Rebecca Chen, Xiaorui Neilson, Jill L Wei, Guo Huang, Yufeng Greene, Tom |
author_facet | Beddhu, Srinivasan Filipowicz, Rebecca Chen, Xiaorui Neilson, Jill L Wei, Guo Huang, Yufeng Greene, Tom |
author_sort | Beddhu, Srinivasan |
collection | PubMed |
description | BACKGROUND: Inflammation is considered one of the major causes of protein-energy wasting in maintenance hemodialysis (MHD) patients. It is unclear whether dietary interventions can impact nutritional status and quality of life in MHD patients with elevated C-reactive protein (CRP) levels. Therefore, we examined the hypothesis that supervised intra-dialysis protein supplementation in MHD patients with elevated plasma CRP will improve protein stores and quality of life. METHODS: A 24 week, two phase, longitudinal, single center, open labeled study of 50 MHD patients with plasma CRP > 3 mg/L was conducted. During the 12-week observation phase dietary advice was provided to increase protein intake to 1.2 g/kg/day. In the 12-week treatment phase 45 g of liquid protein supplement was provided at each dialysis treatment. Protein nitrogen appearance (PNA), mid-arm muscle circumference (MAMC), serum albumin, body mass index (BMI) and quality of life (assessed by Short Form-12 questionnaire) were measured at baseline, 12 and 24 weeks. RESULTS: Median plasma CRP at baseline was 16.0 (IQR 7.7 to 25.1) mg/L. The mean MAMC was 26.5 ± 3.9 cm, BMI 29.2 ± 6.9 kg/m(2) and plasma albumin 3.8 ± 0.3 g/dl. During the intervention period, mean PNA increased by 0.13 g/kg/d (p = 0.01) under a mixed effects model. However, there were no clinically or statistically significant effects on MAMC (p = 0.87), plasma albumin (p = 0.70), BMI (p = 0.09), physical (p = 0.32) or mental (p = 0.96) composite scores. CONCLUSIONS: In MHD patients with elevated plasma CRP but otherwise mostly normal nutritional parameters, intra-dialytic oral protein supplement was effective in increasing protein intake but did not provide a detectable impact on nutritional status or quality of life. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-015-0070-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4477490 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44774902015-06-24 Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study Beddhu, Srinivasan Filipowicz, Rebecca Chen, Xiaorui Neilson, Jill L Wei, Guo Huang, Yufeng Greene, Tom BMC Nephrol Research Article BACKGROUND: Inflammation is considered one of the major causes of protein-energy wasting in maintenance hemodialysis (MHD) patients. It is unclear whether dietary interventions can impact nutritional status and quality of life in MHD patients with elevated C-reactive protein (CRP) levels. Therefore, we examined the hypothesis that supervised intra-dialysis protein supplementation in MHD patients with elevated plasma CRP will improve protein stores and quality of life. METHODS: A 24 week, two phase, longitudinal, single center, open labeled study of 50 MHD patients with plasma CRP > 3 mg/L was conducted. During the 12-week observation phase dietary advice was provided to increase protein intake to 1.2 g/kg/day. In the 12-week treatment phase 45 g of liquid protein supplement was provided at each dialysis treatment. Protein nitrogen appearance (PNA), mid-arm muscle circumference (MAMC), serum albumin, body mass index (BMI) and quality of life (assessed by Short Form-12 questionnaire) were measured at baseline, 12 and 24 weeks. RESULTS: Median plasma CRP at baseline was 16.0 (IQR 7.7 to 25.1) mg/L. The mean MAMC was 26.5 ± 3.9 cm, BMI 29.2 ± 6.9 kg/m(2) and plasma albumin 3.8 ± 0.3 g/dl. During the intervention period, mean PNA increased by 0.13 g/kg/d (p = 0.01) under a mixed effects model. However, there were no clinically or statistically significant effects on MAMC (p = 0.87), plasma albumin (p = 0.70), BMI (p = 0.09), physical (p = 0.32) or mental (p = 0.96) composite scores. CONCLUSIONS: In MHD patients with elevated plasma CRP but otherwise mostly normal nutritional parameters, intra-dialytic oral protein supplement was effective in increasing protein intake but did not provide a detectable impact on nutritional status or quality of life. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-015-0070-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-06-23 /pmc/articles/PMC4477490/ /pubmed/26099512 http://dx.doi.org/10.1186/s12882-015-0070-0 Text en © Beddhu et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Beddhu, Srinivasan Filipowicz, Rebecca Chen, Xiaorui Neilson, Jill L Wei, Guo Huang, Yufeng Greene, Tom Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study |
title | Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study |
title_full | Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study |
title_fullStr | Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study |
title_full_unstemmed | Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study |
title_short | Supervised oral protein supplementation during dialysis in patients with elevated C-reactive protein levels: a two phase, longitudinal, single center, open labeled study |
title_sort | supervised oral protein supplementation during dialysis in patients with elevated c-reactive protein levels: a two phase, longitudinal, single center, open labeled study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477490/ https://www.ncbi.nlm.nih.gov/pubmed/26099512 http://dx.doi.org/10.1186/s12882-015-0070-0 |
work_keys_str_mv | AT beddhusrinivasan supervisedoralproteinsupplementationduringdialysisinpatientswithelevatedcreactiveproteinlevelsatwophaselongitudinalsinglecenteropenlabeledstudy AT filipowiczrebecca supervisedoralproteinsupplementationduringdialysisinpatientswithelevatedcreactiveproteinlevelsatwophaselongitudinalsinglecenteropenlabeledstudy AT chenxiaorui supervisedoralproteinsupplementationduringdialysisinpatientswithelevatedcreactiveproteinlevelsatwophaselongitudinalsinglecenteropenlabeledstudy AT neilsonjilll supervisedoralproteinsupplementationduringdialysisinpatientswithelevatedcreactiveproteinlevelsatwophaselongitudinalsinglecenteropenlabeledstudy AT weiguo supervisedoralproteinsupplementationduringdialysisinpatientswithelevatedcreactiveproteinlevelsatwophaselongitudinalsinglecenteropenlabeledstudy AT huangyufeng supervisedoralproteinsupplementationduringdialysisinpatientswithelevatedcreactiveproteinlevelsatwophaselongitudinalsinglecenteropenlabeledstudy AT greenetom supervisedoralproteinsupplementationduringdialysisinpatientswithelevatedcreactiveproteinlevelsatwophaselongitudinalsinglecenteropenlabeledstudy |